What Is Pancragen?
Pancragen is a tetrapeptide bioregulator developed by Professor Vladimir Khavinson targeting the pancreas — both its endocrine function (insulin and glucagon secretion from islets of Langerhans) and its exocrine function (digestive enzyme production from acinar cells). It is designed to restore normal pancreatic cellular activity that declines with aging. It was developed by Prof. Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology.
Pancreatic Aging
The pancreas undergoes significant age-related changes: exocrine acinar cell number and activity decline, reducing digestive enzyme output and contributing to malabsorption. Beta cell mass and insulin secretory capacity decrease, contributing to the impaired first-phase insulin response characteristic of age-related glucose dysregulation. Pancragen is designed to restore normal activity in both pancreatic compartments.
Research Applications
Animal studies have demonstrated improved pancreatic histological scores, preserved islet architecture, and normalized insulin secretion parameters in aged animals treated with Pancragen. Studies also document improved exocrine enzyme production. Russian clinical research has examined Pancragen for age-related pancreatic insufficiency and borderline glucose regulation in elderly subjects. It is sometimes combined with Svetinorm (liver bioregulator) for comprehensive metabolic health support.
Mechanism of Action
DNA / chromatin interaction and epigenetic modulation: Pancragen is proposed to penetrate cellular membranes, localize to the nucleus, and interact with DNA and histones. It may bind chromatin complexes, alter promoter methylation patterns at key genes (PDX1, NGN3), and shift transcription toward a more youthful or regenerative profile. Murine studies show upregulation of transcription factors critical for pancreatic endocrine cell maturation — Pdx1, Pax6, Ptf1a, Foxa2, Nkx2.2, and Pax4 — supporting beta cell differentiation and functional maintenance.
Pancreatic endocrine function and glucose metabolism: Non-human primate studies (IM, 10-day course) showed improved glucose disappearance rate and normalized insulin and C-peptide dynamics. A small human study in elderly type 2 diabetic subjects showed reduced fasting glucose, improved OGTT response, and reduced insulin resistance index. Laboratory models further support modulation of insulin and glucagon secretion and regulation of digestive enzyme production.
Anti-apoptotic and cellular aging effects: Pancragen reduces pro-apoptotic p53 expression and increases anti-apoptotic Mcl-1 in cell models, suggesting a cytoprotective role under metabolic and oxidative stress. Antioxidant potential has been hypothesized — either through free radical scavenging or upregulation of endogenous defenses. Plasma half-life is expected to be short (minutes to a few hours, like other ultrashort tetrapeptides), but functional metabolic effects persist up to several weeks post-cycle, consistent with transcriptional and epigenetic changes that outlast peptide plasma presence.
Quick Reference
Member reference tables summarize the compound's research parameters.
Research Indications
Pancreatic Endocrine Function & Glucose Metabolism
Non-human primate study (10-day IM course) showed normalized glucose disappearance rate and improved insulin and C-peptide dynamics after glucose challenge. Small human T2D trial in elderly subjects reported reduced fasting glucose, improved OGTT results, and reduced insulin resistance index — authors concluded Pancragen is a promising approach to correcting insulin resistance in elderly individuals.
Insulin Resistance Correction in Elderly T2D
Russian clinical data from elderly type 2 diabetic subjects showed significant reductions in fasting glucose, oral glucose tolerance improvements, and decreased insulin resistance index after a 10-day Pancragen course. Represents the strongest clinical signal in the Pancragen literature.
Pancreatic Endocrine Function & Glucose MetabolismSupported Research
Pancreatic Cell Differentiation & Epigenetic Regulation
Murine models show upregulation of key transcription factors for endocrine cell maturation: Pdx1, Pax6, Ptf1a, Foxa2, Nkx2.2, and Pax4. Promoter methylation changes at PDX1 and NGN3 suggest a shift toward more youthful gene expression profiles in pancreatic cells. These effects position Pancragen as a research tool for epigenetic studies in pancreatic tissue.
Exocrine Pancreatic Function
Animal studies document improved exocrine enzyme production and preserved acinar cell histological scores alongside endocrine improvements. Age-related decline in digestive enzyme output represents a secondary research target alongside the endocrine/metabolic work.
Pancreatic Cell Differentiation & Epigenetic RegulationPreliminary Data
Cellular Protection & Anti-Apoptotic Effects
Cell culture and laboratory models show reduced p53 expression and increased anti-apoptotic Mcl-1, suggesting a cytoprotective role in pancreatic cells under metabolic or oxidative stress. Hypothesized antioxidant potential (free radical scavenging or endogenous antioxidant upregulation) also noted in preclinical work. No human evidence for these mechanisms.
Longevity & Multi-Cycle Metabolic Resilience
Bioregulator framework proposes that 2–3 cycles/year of Pancragen maintains or gradually improves metabolic resilience and pancreatic function in aging models. Evidence is limited to non-randomized, primarily Russian observational data with small samples and short follow-up. Long-term human RCT data does not exist.
Cellular Protection & Anti-Apoptotic EffectsPreclinical Only
Research Protocols (Educational Only)
This member section describes parameters reported in the research literature.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
This member section describes parameters reported in the research literature.
Peptide Interactions
This member section summarizes reported compound interactions and evidence limitations.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
This member section discusses research safety considerations and uncertainties.
Quality Indicators
Reported Research Time Points
This member section summarizes reported research time points.
Research Citations
- Correction of impaired glucose tolerance using tetrapeptide (Pancragen) in old female rhesus monkeys
Goncharova ND, Ivanova LG, Oganyan TE — Adv Gerontol, 2015 - Impact of tetrapeptide Pancragen on endocrine function of the pancreas in old monkeys
Goncharova ND, Ivanova LG, Oganian TÉ — Adv Gerontol, 2014 - Peptide regulation of aging — Khavinson bioregulator family review
Khavinson VKh, Linkova NS et al. — Bull Exp Biol Med, 2013 - Short peptides regulate gene expression, protein synthesis and replicative lifespan of human fibroblasts
Khavinson VKh et al. — Bull Exp Biol Med, 2014 - Peptide bioregulators as a new class of geroprotectors: from laboratory research to clinical studies
Khavinson V, Linkova N, Diatlova A, Trofimova S — Biomedicines, 2021 - Khavinson development attribution. Existing stored entry reference; Existing stored entry reference
Pancragen is a tetrapeptide bioregulator developed by Professor Vladimir Khavinson targeting the pancreas — both its endocrine function (insulin and glucagon secretion from islets of Langerhans) and its exocrine function (digestive enzyme production from acinar cells). It is designed to restore normal pancreatic cellular activity that declines with aging.